Article in Translational medicine of aging, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
7 authors.
Ana R SilversteinLeonard Davis School of Gerontology, University of Southern California, Los Angeles, CA, USA.
Melanie K FloresLeonard Davis School of Gerontology, University of Southern California, Los Angeles, CA, USA.
Brendan MillerLeonard Davis School of Gerontology, University of Southern California, Los Angeles, CA, USA.
Su-Jeong KimLeonard Davis School of Gerontology, University of Southern California, Los Angeles, CA, USA.
Kelvin YenLeonard Davis School of Gerontology, University of Southern California, Los Angeles, CA, USA.
Hemal H MehtaLeonard Davis School of Gerontology, University of Southern California, Los Angeles, CA, USA.
Pinchas CohenLeonard Davis School of Gerontology, University of Southern California, Los Angeles, CA, USA.
Funding
RESEARCH TRAINING IN GERONTOLOGYT32AG000037 · NIA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI JENNIFER A AILSHIRE, EILEEN M CRIMMINS · 1985 to 2026
$13.2M
Role of the Mitochondrial Peptide Humanin in Regulating Aging and HealthspanP01AG055369 · NIA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI LONGO, VALTER D. · 2018 to 2023
$12.4M
Ethnic-specific Effects of Mitochondrial DNA Variants and Environmental Factors on Cognitive Functioning and DementiaR01AG068405 · NIA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI COHEN, PINCHAS, CRIMMINS, EILEEN M · 2020 to 2024
$3.6M
Humanin is an AD resilience factor through its interaction with APOE4RF1AG061834 · NIA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI COHEN, PINCHAS · 2018 to 2018
$3.3M
Metformin-Regulated Mitochondrial Peptides and their Effects on AgingR01AG069698 · NIA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI COHEN, PINCHAS · 2020 to 2024
$2.1M
Ethnic-Specific Mitochondrial DNA Variations that Contribute to DementiaR56AG062693 · NIA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI COHEN, PINCHAS, CRIMMINS, EILEEN M · 2019 to 2019
Recent advancements in genomic, transcriptomic, proteomic, and metabolomic techniques have prompted fresh inquiry in the field of aging. Here, we outline the application of these techniques in the context of the mitochondrial genome and suggest their potential for use in exploring the biological mechanisms of the aging immune system.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Mito-Omics and immune function: Applying novel mitochondrial omic techniques to the context of the aging immune system. · full record | OpenQuestion